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The treatment of Parkinson’s disease with grafts of fetal ventral mesencephalic tissue has shown some
success, but can result in graft-induced dyskinesias (GIDs). Recently in Science Translational Medicine,
Politis et al. (2010) demonstrate that GIDs may originate from serotoninergic neurons that are cografted in
these transplants.Parkinson’s disease (PD) is a common
neurodegenerative disorder of the central
nervous system (CNS). PD is character-
ized by the loss of neurons at a number
of CNS and non-CNS sites, which is
accompanied by the formation of a-synu-DA 5HT
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Figure 1. Proposed Mechanism
of Buspirone Attenuation of GID
(A) In the graft of all patients there is a mixture
of dopaminergic and serotonergic neurons,
the release of dopamine (orange dots) can
be regulated by presynaptic dopamine trans-
porters (DAT), and the release of 5HT (blue
dots) by serotonin transporters (5-HTT). In
patients without GIDs, these neurons take
up their own neurotransmitter and there is no
real dialog between them.
(B) In patients with GIDs, the serotonergic
terminals hyperinnervate the striatum in the
grafted patient, and large amounts of 5HT
are released, which may be able to reverse
or alter the capacity of the DAT, thereby
causing a greater release of dopamine from
the grafted dopaminergic nerve terminals. In
addition, the 5HT transporter can also take
up dopamine and then release it as a false
transmitter from the 5HT nerve terminal.
(C) Buspirone, a selective 5HT1A agonist, was
used to activate the presynaptic 5HT1A
receptor to dampen the release of serotonin
from serotonergic terminals. Reduced levels
of 5HT leads to a change in DAT and 5-HTT
activity and restores more regulated dopa-
mine release from the grafted dopaminergic
neurons.clein-positive Lewy bodies (Braak
et al., 2006). The etiology of this
condition remains obscure in the
majority of cases, although nearly 50
years ago it was recognized that
patients experience degeneration of
the nigrostriatal dopaminergic path-
way, and that using dopaminergic
drugs to substitute for this loss can
ameliorate many of the symptoms in
the short term. However, these
agents are not curative and with time
complications arise with their use,
including the development of unpre-
dictablemotor responses (on-off phe-
nomena) and the genesis of
abnormal, involuntary dyskinetic
movements (L-dopa-induced dyski-
nesias, LIDs). As a result, more defin-
itive reparative strategies have been
sought, one of which involves using
grafts containing fetal dopaminergic
neuroblasts derived from the devel-
oping human ventral mesencephalon
(VM). These transplants, when placed
into the striatum of patients with PD,
can produce clear clinical benefits,
albeit inconsistently (Goya et al.,
2007). The heterogeneity of patient
responses has always been an area
of concern, but an additional serious
problem with this approach was iden-
tified in the early part of this century
during two double-blind, placebo-
controlled trials. These studies
revealed that the grafts themselves
could induce dyskinetic movements,148 Cell Stem Cell 7, August 6, 2010 ª2010 Etermed graft-induced dyskinesias (GIDs)
(reviewed in Goya et al., 2007). GIDs are
phenomenologically different from LIDs
and are not obviously related to L-dopa
medication and persist in the absence of
anti-PD medication. The etiology of GIDslsevier Inc.has been the subject of intense debate,
and a predominant hypothesis under
examination names dopamine (DA) as
the causative agent and suggests that
the grafts either release too much dopa-
mine or release it unevenly across thestriatal complex (Figure 1; Ma et al.,
2002). Recently, however, attention
has turned toward the population of
serotoninergic or 5-hydroxytrypta-
mine (5HT) neurons within the graft,
which arise developmentally just
caudal to the VM and are therefore
also transplanted.
This suggestion that the 5HT cells
within the VM transplant may be im-
portant has its origins in recent work
on LIDs, where it has been shown
that exogenously supplied L-dopa
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by the serotonergic terminals (Tanaka
et al., 1999) but not inactivated because
such cells lack dopamine transporters.
Nevertheless, targeting the presynaptic
inhibitory serotonergic receptors can
attenuate LIDs in a rat model of PD (Mu-
n˜oz et al., 2008), and selective lesioning
of serotonergic afferent projections to
the striatum can almost completely
abolish their development (Carta et al.,
2007). It is therefore logical to assume
that some similar process may be taking
place in the VM transplants (Mendez
et al., 2008), and as such these cells could
be at least partially responsible for the
development of GID. In a new study pub-
lished recently in Science Translational
Medicine (Politis et al., 2010), the authors
use PET imaging and the specific sero-
tonin transporter ligand, 11C-DASB, to
explore this possibility in two VM-grafted
PD patients that exhibit GIDs. Their
results indicate that these patients have
a 5HT hyperinnervation of the grafted
striatum, which in itself is not surprising
given what we already know about the
pathology of such grafts. However, the
authors extend their findings to show
that a specific 5HT1A agonist, buspirone,
lessens the GIDs without any worsening
of the patients’ underlying Parkinsonism.
This result suggests that the drug works
relatively selectively by activating the
presynaptic 5HT autoreceptor (Figure 1),
which in turn leads to a reduction in dopa-
mine release from the transplanted
neurons.
This hypothesis is intriguing, yet it
remains unclear how exactly this dialog
between the serotonin and dopaminergic
neurons leads to GIDs. For example, one
would anticipate that the grafted dopami-
nergic neurons should take up any
excessive dopamine released within the
transplant. However, the authors propose
that the defect stems fromchanges in howthe dopamine transporter behaves during
serotoninergic hyperinnervation. There is
evidence from other studies to suggest
that the dopamine transporter can change
its activity and direction of dopamine flux
as a function of 5HT, but activity modula-
tion of this sort has not been shown in
this study in these patients. Furthermore,
it is not clear why only some transplanted
patients develop GIDs, given that all VM
grafts contain a proportion of developing
5HT neurons. Indeed, even in the two
cases reported by Politis and colleagues,
the extent of GIDs is similar despite the
presence of different levels of 5HT reinner-
vation within the striatum. Finally, accord-
ing to the authors’ model, it would be
expected that GIDs should worsen with
L-dopa therapy, and yet this pattern has
not been observed thus far.
Overall, the findings reported in this
paper highlight the importance of nondo-
paminergic networks in the genesis of
dyskinesias, and therefore attention
must be paid to this relationship in new
trials of fetal VM transplants for PD. In
contrast, these findings may present
a less serious issue for the world of stem
cell transplantation in PD, given that the
goal of the field has always been to pro-
duce a relatively uniform population of
true nigral dopaminergic neurons.
Achieving this goal seems increasingly
likely, although no consensus yet exists
as to the definition of a true nigral dopami-
nergic neuron (Li et al., 2008). Neverthe-
less, multipotent stem cell sources can
be engineered to selectively generate
specific cell fates and the current data
from Lindvall and colleagues suggests
that it will be important to avoid the
genesis of 5HT neurons in this setting.
However, it is likely that Politis et al.
have only partly explained the source of
GIDs and that the location of the trans-
planted dopaminergic neurons within the
striatal complex and their local innerva-Cell Stem Celtion capabilities also contribute to the
genesis of these abnormal movements
(Carlsson et al., 2006).
Finally, it is worth noting that this study
shows that dopaminergic cell transplants
produce benefits on motor control that
may take years to mature, as is evident
by the reduction in UPDRS more than
13–16 years after grafting. Thus, judging
the success or otherwise of (stem) cellular
repair approaches to PD will, and cannot,
be ultimately achieved via studies with
short follow-up periods.REFERENCES
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